A fragment of human growth hormone (amino acids 177-191) that targets fat metabolism without the side effects of full HGH — no impact on blood sugar, IGF-1, or growth.
AOD-9604 is a modified fragment of the C-terminus of human growth hormone. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) through the same beta-3 adrenergic receptor pathway as full HGH, but without activating the IGF-1 axis. This means fat metabolism benefits without the fluid retention, insulin resistance, or growth effects associated with full HGH therapy.
For women concerned about GH therapy side effects (joint pain, fluid retention, insulin resistance), AOD-9604 offers a targeted alternative that isolates the fat metabolism benefits. It is particularly relevant for menopausal women experiencing stubborn fat accumulation who want metabolic support without the complexity of full GH secretagogue therapy.
Generally well-tolerated. Mild injection site reactions are the most common side effect. Unlike full HGH, AOD-9604 does not cause fluid retention, carpal tunnel symptoms, insulin resistance, or other growth hormone-related side effects. Long-term safety data is limited.
No. Unlike full HGH, AOD-9604 does not activate the IGF-1 axis and does not impact blood sugar or insulin sensitivity. This is one of its primary advantages for women with metabolic concerns.
AOD-9604 and GLP-1 agonists work through completely different mechanisms and are sometimes used together in integrative protocols. Always discuss combination therapy with your healthcare provider.
Part of our Weight Management hub.
Medical Disclaimer: This profile is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide therapy.
Affiliate Disclosure: Vendor links are affiliate partnerships. Full disclosure →
Take our 60-second quiz for a personalized recommendation.
Find Your Peptide →